Townsquare Capital LLC Sells 1,082 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Townsquare Capital LLC reduced its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 4.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,188 shares of the company’s stock after selling 1,082 shares during the quarter. Townsquare Capital LLC’s holdings in Castle Biosciences were worth $591,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CSTL. Barclays PLC increased its stake in shares of Castle Biosciences by 310.7% in the third quarter. Barclays PLC now owns 52,301 shares of the company’s stock valued at $1,491,000 after buying an additional 39,567 shares in the last quarter. JPMorgan Chase & Co. increased its position in Castle Biosciences by 165.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company’s stock valued at $1,980,000 after acquiring an additional 43,241 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Castle Biosciences by 1.1% during the third quarter. Geode Capital Management LLC now owns 624,683 shares of the company’s stock worth $17,820,000 after purchasing an additional 7,004 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Castle Biosciences by 2.7% during the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after purchasing an additional 40,377 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Castle Biosciences by 9.8% in the third quarter. State Street Corp now owns 680,001 shares of the company’s stock valued at $19,394,000 after purchasing an additional 60,924 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Castle Biosciences Stock Up 1.2 %

Shares of NASDAQ CSTL opened at $21.51 on Friday. Castle Biosciences, Inc. has a 52-week low of $16.97 and a 52-week high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The stock has a market cap of $620.46 million, a P/E ratio of 107.56 and a beta of 1.11. The firm has a 50 day moving average price of $21.66 and a 200 day moving average price of $26.85.

Insider Activity

In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total value of $221,613.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Derek J. Maetzold sold 2,130 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $19.52, for a total value of $41,577.60. Following the completion of the sale, the insider now owns 78,335 shares of the company’s stock, valued at $1,529,099.20. This trade represents a 2.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,085 shares of company stock valued at $748,045 in the last quarter. Company insiders own 7.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on CSTL. Guggenheim set a $30.00 price objective on Castle Biosciences and gave the stock a “buy” rating in a report on Friday, March 28th. Stephens reaffirmed an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research note on Thursday, January 2nd. Finally, Robert W. Baird lifted their price objective on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Castle Biosciences presently has an average rating of “Buy” and a consensus price target of $38.75.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.